Mod GRF 1-29
Aliases: CJC-1295 bez DAC · CJC-1295 no DAC · Modified GRF (1-29) · CJC-1295 without DAC
Last verified: 2026-09-23
The short version
Modified GHRH(1–29) with 4 amino-acid substitutions — enzyme-resistant but still short-acting (~30 min half-life), preserving physiological GH pulsatility. The "gold standard" partner to Ipamorelin. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical and early clinical data for GHRH analogues; Mod GRF itself was never formally developed as a drug. Status: research chemical. Not approved; WADA-banned (S2).
Identity & type
- Molecular type
- analog
- Origin
- Modified GHRH(1–29) with 4 amino-acid substitutions — enzyme-resistant but still short-acting (~30 min half-life), preserving physiological GH pulsatility.
Mechanism of action
GHRH receptor agonist; synergizes with ghrelin-pathway agonists (GHRPs) for maximal pulsatile GH peaks.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for Mod GRF 1-29. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
100 mcg SC 1–3× daily, usually before bed, together with Ipamorelin. CJC without DAC gives a shorter, more physiological pulse — taken before bed or pre-workout. The community almost exclusively pairs it with ipamorelin (the "CJC+Ipa stack") for sleep, recovery and mild muscle gain.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
CJC without DAC gives a shorter, more physiological pulse — taken before bed or pre-workout. The community almost exclusively pairs it with ipamorelin (the "CJC+Ipa stack") for sleep, recovery and mild muscle gain.
Protocol — official vs community
Official / label
No approved product. Research use: 100–300 mcg SC, best matched to natural GH pulses (pre-sleep or post-training).
Duration: Short half-life (~30 min) means timing matters more than dose.
Also written as CJC-1295 no-DAC or GRF(1-29) with DAC-inhibiting modifications.
Community (anecdotal)
100 mcg SC 2–3× daily (morning, post-workout, pre-bed), stacked with a GHRP such as ipamorelin.
- Cycle:
- 8–12 weeks.
- Break:
- 4 weeks off.
Pulsatile by design — pairs with GHRPs because the combination mimics natural GH release architecture.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical and early clinical data for GHRH analogues; Mod GRF itself was never formally developed as a drug.
Preclinical evidence
Preclinical and early clinical data for GHRH analogues; Mod GRF itself was never formally developed as a drug.
Known risks
- Injection-site redness/pain, brief flushing, headache.characterized
- Unregulated injectable supply — sterility, purity and accurate dose not assuredtheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.